These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 3494456)

  • 1. Infrequency of anticentromere antibody in patients without systemic sclerosis and without Raynaud's phenomenon.
    Migliaresi S; Picillo U; Terri G; Improta RD; La Palombara F; Giordano M
    Arthritis Rheum; 1987 Mar; 30(3):358-9. PubMed ID: 3494456
    [No Abstract]   [Full Text] [Related]  

  • 2. Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies.
    Kallenberg CG; Pastoor GW; Wouda AA; The TH
    Ann Rheum Dis; 1982 Aug; 41(4):382-7. PubMed ID: 7051989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The clinical significance of anti-ENA antibodies and anticentromere antibody (ACA) in patients with sclerodermatous skin changes and Raynaud's phenomenon].
    Uchida K; Kondo H; Kashiwazaki S
    Ryumachi; 1984 Aug; 24(4):241-9. PubMed ID: 6334895
    [No Abstract]   [Full Text] [Related]  

  • 4. Longitudinal study of patients with anticentromere antibody.
    Takehara K; Soma Y; Igarashi A; Kikuchi K; Tamaki T; Ishibashi Y
    Dermatologica; 1990; 181(3):202-6. PubMed ID: 2135387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CREST syndrome: a distinct serologic entity with anticentromere antibodies.
    Fritzler MJ; Kinsella TD
    Am J Med; 1980 Oct; 69(4):520-6. PubMed ID: 6968511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between fluorescent antinuclear antibodies, capillary patterns, and clinical features in scleroderma spectrum disorders.
    Chen ZY; Silver RM; Ainsworth SK; Dobson RL; Rust P; Maricq HR
    Am J Med; 1984 Nov; 77(5):812-22. PubMed ID: 6333815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Dysimmune rheumatism in Raynaud's syndrome (inflammatory rheumatism, Raynaud's syndrome, speckled antinuclear factors and anti-ribonucleoprotein antibody): a new syndrome?].
    Appelboom T; Kahn MF; Peltier AP; de SEZE S
    Ann Med Interne (Paris); 1974 Nov; 125(11):841-8. PubMed ID: 4218716
    [No Abstract]   [Full Text] [Related]  

  • 8. Anticentromere antibodies in rheumatologic practice are not consistently associated with scleroderma.
    Tubach F; Hayem G; Elias A; Nicaise P; Haim T; Kahn MF; Meyer O
    Rev Rhum Engl Ed; 1997 Jun; 64(6):362-7. PubMed ID: 9513607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antinuclear antibodies in scleroderma, mixed connective tissue disease and "primary" Raynaud's phenomenon.
    Cruz M; Mejia G; Lavalle C; Cortes JJ; Reyes PA
    Clin Rheumatol; 1988 Mar; 7(1):80-6. PubMed ID: 3261675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early detection of scleroderma spectrum disorders in patients with Raynaud's phenomenon.
    Takehara K; Soma Y; Ishibashi Y
    Dermatologica; 1991; 183(3):164-8. PubMed ID: 1743381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteins responsible for anticentromere activity found in the sera of patients with CREST-associated Raynaud's phenomenon.
    Kremer L; Alvaro-Gracia JM; Ossorio C; Avila J
    Clin Exp Immunol; 1988 Jun; 72(3):465-9. PubMed ID: 3048807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticentromere antibody: an immunological marker of a subset of systemic sclerosis.
    Chorzelski TP; Jablonska S; Beutner EH; Blaszczyk M; Jarzabek-Chorzelska M; Kencka D; Krasny S; Kumar V; Tchórzewska A
    Br J Dermatol; 1985 Oct; 113(4):381-9. PubMed ID: 3877519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A long-term longitudinal study of anticentromere antibodies.
    Tramposch HD; Smith CD; Senecal JL; Rothfield N
    Arthritis Rheum; 1984 Feb; 27(2):121-4. PubMed ID: 6607733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticentromere antibody and Raynaud's phenomenon.
    Czirják L; Schlammadinger J; Szegedi G
    Dermatologica; 1991; 183(1):55. PubMed ID: 1769420
    [No Abstract]   [Full Text] [Related]  

  • 15. Anticentromere antibody and immunoglobulin allotypes in scleroderma.
    Chen ZY; Fedrick JA; Pandey JP; Silver R; Maricq HR; Fudenberg HH; Dobson RL; Ainsworth SK
    Arch Dermatol; 1985 Mar; 121(3):339-44. PubMed ID: 3883903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticentromere antibody in patients without CREST and scleroderma: association with active digital vasculitis, rheumatic and connective tissue disease.
    Goldman JA
    Ann Rheum Dis; 1989 Sep; 48(9):771-5. PubMed ID: 2802800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anticentromere antibodies. Diagnostic and prognostic value].
    Meyer O; Haïm T
    Nouv Presse Med; 1982 Oct; 11(39):2891-4. PubMed ID: 6755388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunologic markers of systemic scleroderma in children.
    Błaszczyk M; Jabłońska S; Szymańska-Jagiełło W; Jarzabek-Chorzelska M; Chorzelski T
    Pediatr Dermatol; 1991 Mar; 8(1):13-20. PubMed ID: 1907369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Raynaud's phenomenon and anticentromere antibodies].
    Marquet Palomer R; Vilardell Tarrés M; Ordi Ros J
    Med Clin (Barc); 1987 Nov; 89(17):721-4. PubMed ID: 3501051
    [No Abstract]   [Full Text] [Related]  

  • 20. Raynaud's phenomenon possibly induced by a compund drug of tegafur and uracil.
    Seishima M; Izumi T; Kanoh H
    Eur J Dermatol; 2000; 10(1):55-8. PubMed ID: 10694301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.